Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma?

Saygili U., Guclu S., Uslu T., Erten O., Demir N., Onvural A.

GYNECOLOGIC ONCOLOGY, cilt.86, sa.1, ss.57-61, 2002 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 86 Sayı: 1
  • Basım Tarihi: 2002
  • Doi Numarası: 10.1006/gyno.2002.6719
  • Dergi Adı: GYNECOLOGIC ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.57-61
  • Anahtar Kelimeler: CA-125, ovarian carcinoma, cytoreduction, debulking, LONG-TERM SURVIVAL, NEOADJUVANT CHEMOTHERAPY, DEBULKING SURGERY, MONOCLONAL-ANTIBODY, RESIDUAL DISEASE, CANCER, MANAGEMENT
  • Dokuz Eylül Üniversitesi Adresli: Hayır

Özet

Objective. The aim of this study was to investigate the predictive value of serum CA-125 levels to ability of optimal primary cytoreduction in patients with advanced epithelial ovarian carcinoma.